PMVP$1.14
$1.15
Chart
Performance
Key Stats
AI PMVP Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPMV Pharmaceuticals is a speculative biotech company with a focused approach to p53 mutations. While it shows some positive recent performance, its fundamental picture is challenging with no revenue and significant losses. The technicals are mixed, and the thematic tailwinds are highly specific. Investor sentiment is currently neutral.
Thematic
PMV Pharmaceuticals operates in the precision oncology space, targeting p53 mutations. This is a specialized but potentially high-growth area within biotechnology. The success of its lead candidate, rezatapopt, will be a key determinant of its thematic appeal.
Fundamental
PMV Pharmaceuticals is a clinical-stage company with no revenue and significant operating losses. Its balance sheet shows substantial cash but a negative EPS. The company is not yet profitable, and its valuation metrics are not applicable in the traditional sense due to the lack of revenue.
Technical
The stock price has shown recent positive performance over the past month, but the longer-term trend (YTD and 1Y) is negative. Technical indicators are mixed, with some suggesting buying pressure and others indicating potential resistance or overbought conditions at certain intervals.
| Factor | Score |
|---|---|
| Precision Oncology | 75 |
| Drug Development Pipeline | 60 |
| Biotechnology Sector Trends | 65 |
| Regulatory Environment (FDA) | 70 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Debt Level | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 50 |
| Moving Averages | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown strong recent performance, with a 5-day return of 11.02% and a 1-month return of 31.78%, indicating positive momentum.
Mixed but Positive Short-Term Signals
On shorter timeframes (1m, 5m, 10m, 15m, 30m, 1h, 2h, 4h), multiple moving averages (e.g., EMA 10, SMA 10, EMA 20) are signaling 'Buy', suggesting short-term upward price pressure. The 1-day timeframe also shows several 'Buy' signals from moving averages.
Bearish Points (8)
Negative Earnings and High Price-to-Sales
The company has negative Earnings Per Share (EPS) TTM (-$1.18) and consistently negative net income across reported periods. The Price-to-Sales (P/S) ratio is 0.0, likely due to zero reported revenue, which indicates a lack of current sales generation.
No Revenue Generation
Reported revenue is consistently $0 across all periods (TTM, 2024, 2023, 2022, 2021), indicating the company is in the pre-revenue stage and has not yet commercialized its products.
Calendar
August 2025
7
Next Earnings Date
H: $-0.37
A: $-0.39
L: $-0.40
Profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Seasonals
Price Target
8.75 USD
The 39 analysts offering 1 year price forecasts for PMVP have a max estimate of 18.00 and a min estimate of 5.00.